BOT - Anything but charting, page-3545

Unfortunately, BOT is not actively progressing anything to do with synthetic CBD, which is why for the time being I’m out.
The only product being progressed is SB which is not CBD.
I had invested specifically for CBD which will not see the light of day for some time if management is waiting for revenue from SB. That will need at least one more CR and that will mean more dilution for shareholders.

I believe SB was a strategic mistake and we would have been better served to progress 1801 which is eligible foot fast tracking and would require less capital to progress than say acne or rosacea which are both promising but will take longer and require more capital outlay.
Instead 1801 which has now been sitting on ice for what seems to be eons, will continue to sit on ice along with other cbd products.
This also sends a bad message regarding the confidence management have regarding the pipeline they have developed, as their own pipeline takes a backseat to one bought off the shelf.
I still love the CBD IP of this company and will watch closely as to if and when that becomes reactivated.
i am unable to get excited abo
ut SB and will sit on the sidelines until I hear what the plan for cbd is, specifically 1801.
Good luck to everyone holding.